Fasting serum total bile acid levels are associated with insulin sensitivity, islet β-cell function and glucagon levels in response to glucose challenge in patients with type 2 diabetes

Type 2 diabetes (T2D) is characterized by islet β-cell dysfunction and impaired suppression of glucagon secretion of α-cells in response to oral hyperglycaemia. Bile acid (BA) metabolism plays a dominant role in maintaining glucose homeostasis. So we evaluated the association of fasting serum total...

Full description

Saved in:
Bibliographic Details
Published in:Endocrine Journal 2020, Vol.67(11), pp.1107-1117
Main Authors: Wang, Xiao-hua, Xu, Feng, Cheng, Ming, Wang, Xing, Zhang, Dong-mei, Zhao, Li-hua, Cai, Hong‑li, Huang, Hai-yan, Chen, Tong, Zhang, Xiu-lin, Wang, Xue-qin, Cheng, Xing-bo, Su, Jian‑bin, Lu, Yan
Format: Article
Language:English
Subjects:
Beta cells
Bile
Bile acids
Diabetes
Diabetes mellitus (non-insulin dependent)
Glucagon
Glucose
Glucose tolerance
Homeostasis
Hyperglycemia
Insulin
Insulin secretion
Insulin sensitivity
Peptides
Secretion
Total bile acids
Type 2 diabetes
β-cell function
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Type 2 diabetes (T2D) is characterized by islet β-cell dysfunction and impaired suppression of glucagon secretion of α-cells in response to oral hyperglycaemia. Bile acid (BA) metabolism plays a dominant role in maintaining glucose homeostasis. So we evaluated the association of fasting serum total bile acids (S-TBAs) with insulin sensitivity, islet β-cell function and glucagon levels in T2D. Total 2,952 T2D patients with fasting S-TBAs in the normal range were recruited and received oral glucose tolerance tests for determination of fasting and postchallenge glucose, C-peptide and glucagon. Fasting and systemic insulin sensitivity were assessed by homeostasis model assessment (HOMA) and Matsuda index using C-peptide, i.e., ISHOMA-cp and ISIM-cp, respectively. Islet β-cell function was assessed by the insulin-secretion-sensitivity-index-2 using C-peptide (ISSI2cp). The area under the glucagon curve (AUCgla) was used to assess postchallenge glucagon. The results showed ISHOMA-cp, ISIM-cp and ISSI2cp decreased, while AUCgla notably increased, across ascending quartiles of S-TBAs but not fasting glucagon. Moreover, S-TBAs were inversely correlated with ISHOMA-cp, ISIM-cp and ISSI2cp (r = –0.21, –0.15 and –0.25, respectively, p < 0.001) and positively correlated with AUCgla (r = 0.32, p < 0.001) but not with fasting glucagon (r = 0.033, p = 0.070). Furthermore, after adjusting for other clinical covariates by multiple linear regression analyses, the S-TBAs were independently associated with ISHOMA-cp (β = –0.04, t = –2.82, p = 0.005), ISIM-cp (β = –0.11, t = –7.05, p < 0.001), ISSI2cp (β = –0.15, t = –10.26, p < 0.001) and AUCgla (β = 0.29, t = 19.08, p < 0.001). Increased fasting S-TBAs are associated with blunted fasting and systemic insulin sensitivity, impaired islet β-cell function and increased glucagon levels in response to glucose challenge in T2D.
ISSN:0918-8959
1348-4540
DOI:10.1507/endocrj.EJ20-0201